What your doctor may be reading according to Doctors Guide listing of top abstracts in prostate cancer for past 14 days:

1. Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer. Cabrespine A, et al. Urology. 2006 Feb

2. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Michels J, et al.
Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

3. Gynecomastia in patients with prostate cancer: update on treatment options.
Autorino R, et al. 1Clinica Urologica, Seconda Universita degli Studi, Napoli, Italy.

4. Insulin Sensitivity During Combined Androgen Blockade for Prostate Cancer.
Smith MR, J Clin Endocrinol Metab. 2006 Jan 24. Massachusetts General Hospital, Boston, MA.
Free Full text in .pdf

5. Prospective comprehensive assessment of sexual function after retropubic non nerve sparing radical prostatectomy for localized prostate cancer. Trinchieri A,et al. Urology Unit Ospedale A. Manzoni Lecco, Italy. Arch Ital Urol Androl. 2005 Dec. “CONCLUSION: Severe erectile dysfunction was observed in most patients after retropubic radical non nerve sparing prostatectomy, but 50% of candidates for radical treatment presents with abnormal erectile function before surgery when appropriately studied. Patients who will recover erectile function could be identified by NPT test before surgery. Depression associated with the fear for intervention is related with erectile dysfunction measured by IIEF scores before surgery, but depression index scores improve after surgery showing that the role of depression in the maintenance of erectile dysfunction is marginal. Sexual counselling and oral treatment facilitate recovery after surgery in patients with optimal erectile function before treatment.”

For 3 month ratings see Doctors Guide Top Abstracts